Lightyear Capital invests in CuraLinc Healthcare
US personal fairness agency Lightyear Capital has accomplished a strategic funding in CuraLinc Healthcare, a supplier of psychological well being care and wellbeing applications.
No monetary particulars of the funding have been disclosed.
This newest transfer is meant to help the subsequent section of progress for CuraLinc, which makes a speciality of offering worker psychological well being advantages.
Based in 2008, the corporate has grown to develop into a significant participant within the psychological well being sector, supporting roughly 9 million staff and college students worldwide.
The corporate's attain exceeds 4,200 prospects.
CuraLinc's providers are targeted on participating and supporting individuals of their psychological well being. We provide a variety of applications together with worker help, psychological well being counseling, and digital cognitive behavioral remedy.
Entry probably the most complete firm profiles available on the market, powered by GlobalData. Save hours of analysis. Achieve a aggressive edge.
Firm Profile – Free Pattern
Your obtain electronic mail will arrive shortly
We’re satisfied of the distinctive high quality of our firm profiles. Nevertheless, we would like you to take advantage of helpful resolution on your firm, so we provide a free pattern that you would be able to obtain by submitting the shape beneath
By GlobalData
The excellent bundle of providers offered by CuraLinc contains disaster help, group remedy, text-based remedy, digital and psychological well being navigation, and advocacy.
All of those applications are tailor-made to the wants of each staff and college students, making certain accessible and efficient psychological well being care.
Sean Fogarty, Founder and President of CuraLinc, stated: “We’re assured that we are going to profit from Lightyear’s deep area experience in worker advantages and psychological well being, intensive operational community and robust fame as a most popular accomplice for administration groups.
“With this new capital and partnership, we’ll drive additional progress and innovation to raised serve our prospects.”
Davis Polk & Wardwell offered authorized recommendation for the transaction for Lightyear and Locke Lord for CuraLinc.
Monetary advisory providers have been offered by Houlihan Lokey and The Chicago Company for Lightyear and CuraLinc, respectively.
Michael Langer, CEO of Lightyear, stated: “For many of the US inhabitants, entry to care and remedy for psychological well being points stays unaffordable, regardless that roughly one in 4 adults experiences a psychological sickness every year.
“The typical wait time for behavioral well being counseling is six weeks and almost 50% of individuals with psychological sickness don’t search remedy. We consider the worth proposition CuraLinc gives helps tackle among the most important points in healthcare immediately.”
